Accession Number:

AD1092593

Title:

The Prostate Cancer Clinical Trials Consortium: Clinical Research Site Application

Descriptive Note:

Technical Report,30 Sep 2018,30 Sep 2019

Corporate Author:

University of California San Francisco San Francisco United States

Personal Author(s):

Report Date:

2019-10-01

Pagination or Media Count:

20.0

Abstract:

The purpose of the PCCTC is to accelerate the development of novel therapeutics for prostate cancer patients, both by bringing own areas of expertise and contributing substantially to the activity of the consortium in the areas of biomarker development, androgen receptor targeted therapies, aggressive variantneuroendocrine prostate cancer, and theranosticsnovel molecular imaging. Results During the reporting period, 32 patients were accrued across four PCCTC clinical trials, including three trials led by UCSF. One additional LOI was presented at the Scientific Oversight Committee for a PSMA-directed SBRT trial in oligometastatic CRPC.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE